Current and emerging drugs for idiopathic pulmonary fibrosis

Bibliography

• THANNICKAL VJ, FLAHERTY KR, HYZYRCL RC, LYNCH JP III: Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin. Emerging Drugs (2005) 10(4):707-727.
   PubMedGoogle Scholar
• AMERICAN THORACIC SOCIETY; EUROPEAN RESPIRATORY SOCIETY: INTERNATIONAL MULTIDISCIPLINARY CONSENSUS: Classification of the idiopathic interstitial pneumonias. This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am. J. Respir. Crit. Care Med. (2002) 165(2):277-304.
   PubMedGoogle Scholar
• VISSCHER DW, MYERS JL: Histologic spectrum of idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. (2006) 3:322-329.
   Google Scholar
• RAGHU G, WEYCKER D, EDELSHERG J, BRADFORD WZ, OSTER G: Incidence and prevalence of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2006) 174(9):810-816.
   PubMed Web of Science ®Google Scholar
• GHARAEE-KERMANI M, PHAN SH: Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr. Pharm. Des. (2005) 11:3943-3971.
   PubMed Web of Science ®Google Scholar
• ASK K, MARTIN GEM, KOLB M, GAULDIE J: Targeting genes for treatment in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. (2006) 3:389-393.
   PubMedGoogle Scholar
• STRIETER RM: Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest (2005) 128:S526-S532.
   PubMed Web of Science ®Google Scholar
• GROSS TG, HUNNINGHAKE GW: Idiopathic pulmonary fibrosis. N. Engl. J. Med. (2001) 345:517-525.
   PubMed Web of Science ®Google Scholar
• GHARAEE-KERMANI M, GYETKO MR, HU B, PHAN SH: New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm. Res. (2007) 24(5):819-841.
   PubMed Web of Science ®Google Scholar
• GHARAEE-KERMANI M, NOZAKI Y, HATANO K, PHAN SH: Lung interlukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine (2001) 5:138-147.
   Google Scholar
• GHARAEE-KERMANI M, PHAN SH: Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr. Pharm. Des. (2001) 7:1083-1103.
   PubMed Web of Science ®Google Scholar
• SWIGRIS JJ, BROWN KK: Idiopathic pulmonary fibrosis: a decade of progress. J. Bars. Pneumol. (2006) 32:249-260.
   PubMedGoogle Scholar
• LAMA VN, PHAN SH: The extrapulmonary origin of fibroblasts. Proc. Am. Thorac. Soc. (2006) 3:373-376.
   PubMedGoogle Scholar
• WILLIS BC, DUBOIS RM, BROK Z: Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. (2006) 3:377-382.
   PubMedGoogle Scholar
• HASHIMOTO N, JIN H, LIU T, CHENSUE SW, PHAN SH: Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. (2004) 113:243-252.
   PubMed Web of Science ®Google Scholar
• DUNSMORE SE, SHAPIRO SD: The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J. Clin. Invest. (2004) 113:180-182.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RJ, BURDICK MD, HONG K et al.: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. (2004) 114:438-446.
   PubMed Web of Science ®Google Scholar
• HINZ B, PHAN SH, THANNICKAL VJ, GALLI A, BOCHATON-PIALLAT ML, GABBIANI G: The myofibroblast one function, multiple origins. Am. J. Pathol. (2007) 170(6):1807-1816.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, FLAHERTY KR, MARTINEZ FJ, LYNCH JP III: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin. Pharmacother. (2004) 5(8):1671-1686.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, TOEWS GB, WHITE ES, LYNCH JP III, MARTINEZ FJ: Mechanisms of pulmonary fibrosis. Annu. Rev. Med. (2004) 55:395-417.
   PubMed Web of Science ®Google Scholar
• SELMAN M: From anti-inflammatory drugs through antifibrotic agents to lung transportation. A long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest (2002) 123(3):759-761.
   Web of Science ®Google Scholar
• GRIBBIN J, HUBBARD RB, LE JEUNE I, SMITH, CJ, WEST J, TATA LJ: The incidence and mortality of Idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax (2006) 61:980-985.
   PubMed Web of Science ®Google Scholar
• BJORAKER JA, RYU JH, ADWIN MK et al.: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (1998) 157:199-203.
   PubMed Web of Science ®Google Scholar
• WELL AU, HOGABOAM CM: Update in diffuse parenchymal lung disease 2006. Am. J. Respir. Crit. Care Med. (2007) 175(7):655-660.
   PubMed Web of Science ®Google Scholar
• MANNINO DM, ETZEL RA, PARRISH RG: Pulmonary fibrosis deaths in the United States, 1979 – 1991. An analysis of multiple-cause mortality data. Am. J. Respir. Crit. Care Med. (1996) 153(5):1548-1552.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ DA, HELMERS RA, GALVIN JR et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (1994) 149(2 Part 1):450-454.
   PubMed Web of Science ®Google Scholar
• WALTER N, HAROLD RH, COLLARAD HR, KING TE Jr: Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. (2006) 3:330-338.
   PubMedGoogle Scholar
• LUPPI F, CERRI S, BEGHE B, FABBRI LM, RICHELDI L: Corticosteroids and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir. Med. (2004) 98:1035-1044.
   PubMed Web of Science ®Google Scholar
• ABDELAZIZ MM, SAMMAN SY, WALI SO, HAMAD MM: Treatment idiopathic pulmonary fibrosis: is there anything new. Respiratory (2005) 10:284-289.
   Google Scholar
• DU BOIS RM: Is idiopathic pulmonary fibrosis now treatable? Am. J. Respir. Crit. Care Med. (2005) 171(9):939-940.
   PubMed Web of Science ®Google Scholar
• BOUROS D, ANTONIOU KM: Current and future therapeutic approaches in idiopathic. Eur. Respir. J. (2005) 26:693-702.
   PubMed Web of Science ®Google Scholar
• BHATT N, BARAN CP, ALLEN J, MAGRO C, MARSH CB: Promising pharmacologic innovations in treating pulmonary fibrosis. Curr. Opin. Pharm. (2006) 6:284-292.
   PubMed Web of Science ®Google Scholar
• RAGHU G, DEPASO WJ, CAIN K et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. (1991) 144(2):291-296.
   PubMed Web of Science ®Google Scholar
• ZISMAN DA, LYNCH JP III, TOEWS GB, KAZEROONI EA, FLINT A, MARTINEZ FJ: Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest (2000) 117(6):1619-1626.
   PubMed Web of Science ®Google Scholar
• COULTAS DB: Epidemiology of idiopathic pulmonary fibrosis. In: Idiopathic Pulmonary Fibrosis. Lynch JP III (Ed.), Dekker, Inc., New York, USA (2004):1-30.
   Google Scholar
• LAMA VN, FLAHERTY KR, TOEWS GB et al.: Prognostic value of desaturation during a six-minute-walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. (2003) 168:1084-1090.
   PubMed Web of Science ®Google Scholar
• HALLSTRAND TS, BOITNAO LJ, JOHNSON WC, SPADA CA, HAYES JG, RAGHU G: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. (2005) 25:96-103.
   PubMed Web of Science ®Google Scholar
• LEDERER DJ, ACRASOY SM, WILT JS, D'OVIDIO F, SONETT JR, KAWUT SM: Six minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2006) 174:659-664.
   PubMed Web of Science ®Google Scholar
• MAPLEL DW, HUNT WC, UTTON R, BAUMGARTNER KB, SAMET JM, COULTAS DB: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax (1998) 53:469-476.
   PubMed Web of Science ®Google Scholar
• BARDALES RH, XIE SS, SCHAEFER RF, HSU SM: Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am. J. Pathol. (1996) 149(3):845-852.
   PubMed Web of Science ®Google Scholar
• UHAL BD, JOSHI I, HUGHES WF, RAMOS C, PARDO A, SELMAN M: Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am. J. Physiol. (1998) 275:L1192-L1199.
   PubMed Web of Science ®Google Scholar
• UHAL BD, JOSHI I, TRUE LA et al.: Fibroblast isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am. J. Physiol. (1995) 269:L819-L828.
   PubMed Web of Science ®Google Scholar
• SKALLI O, SCHÜRCH W, SEEMAYER T: Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab. Invest. (1989) 60:275-285.
   PubMed Web of Science ®Google Scholar
• PHAN SH: Role of the myofibroblast in pulmonary fibrosis. Kidney Int. (1996) 49(54):S46-S48.
   Web of Science ®Google Scholar
• SCHISSEI LS, MATTHEW LD: Telomerase, myofibroblasts, and pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. (2006) 34:520-522.
   PubMed Web of Science ®Google Scholar
• GHARAEE-KERMANI M, PHAN SH: Role of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. In: Idiopatic Pulmonary Fibrosis. Lynch JP III (Ed.), Marrcel Dekker, Inc., New York, USA (2004):509-561.
   Google Scholar
• WILLIS BC, LIEBLER JM, LUBY-PHELPS K et al.: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. (2005) 166:1321-1332.
   PubMed Web of Science ®Google Scholar
• SWIGRIS JJ, KUSCHNER WJ, KELSEY JL, GOULD MK: Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator. Chest (2005) 127:275-283.
   PubMed Web of Science ®Google Scholar
• IYER SN, HYDE DM, GIRI SN: Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation (2000) 24(5):477-491.
   PubMed Web of Science ®Google Scholar
• OKU H, NAKAZATO H, HORIKAWA T, TSURUTA Y, SUZUKI R: Pirfenidone suppresses TNF-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. (2002) 446(1-3):167-176.
   PubMed Web of Science ®Google Scholar
• NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel anti-fibrotic agent pirfenidone suppresses TNF-α at the translational level. Eur. J. Pharmacol. (2002) 446(1-3):177-185.
   PubMed Web of Science ®Google Scholar
• LURTON JM, TREJO T, NARAYANAN AS: Pirfenidone inhibits the stimulatory effects of profibrotic cytokines of human lung fibroblasts in vitro. Am. J. Respir. Crit. Care Med. (1996) 153:A403.
   Google Scholar
• IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 291(1):367-373.
   PubMed Web of Science ®Google Scholar
• GURUJEYALAKSHMI G, HOLLINGER MA, GIRI SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. (1999) 276(2 Part 1):L311-L318.
   PubMed Web of Science ®Google Scholar
• GIRI SN, LEONARD S, SHI X, MARGOLIN SB, VALLYATHAN V: Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. (1999) 18(3):169-177.
   PubMedGoogle Scholar
• IYER SN, WILD JS, SCHIEDT MJ, HYDE DM, MARGOLIN SB, GIRI SN: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. (1995) 125(6):779-785.
   PubMed Web of Science ®Google Scholar
• AL-BAYATI MA, XIE Y, MOHR FC, MARGOLIN SB, GIRI SN: Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem. Pharmacol. (2002) 64(3):517-525.
   PubMed Web of Science ®Google Scholar
• TADA S, NAKAMUTA M, ENJOJI M et al.: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. (2001) 28(7):522-527.
   PubMed Web of Science ®Google Scholar
• WALLER JR, MURPHY GJ, METCALFE MS et al.: Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant. Proc. (2001) 33(7-8):3816-3818.
   PubMed Web of Science ®Google Scholar
• RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. (1999) 159(4 Part 1):1061-1069.
   PubMed Web of Science ®Google Scholar
• NAGAI S, HAMADA K, SHIGEMATSU M, TANIYAMA M, YAMAUCHI S, IZUMI T: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. (2002) 41(12):1118-1123.
   PubMed Web of Science ®Google Scholar
• GAHL WA, BRANTLY M, TROENDLE J et al.: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. (2002) 76(3):234-242.
   PubMed Web of Science ®Google Scholar
• AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040-1047.
   PubMed Web of Science ®Google Scholar
• SIMONE NL, SOULE BL, GERBER L et al.: Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat. Oncol. (2007) 2:19.
   PubMed Web of Science ®Google Scholar
• ANTONIU SA: Pirfenidone for idiopathic pulmonary fibrosis. Expert Opin. Investig. Drugs (2006) 15(7):823-828.
   PubMed Web of Science ®Google Scholar
• ANTONIU SA: Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert Opin. Investig. Drugs (2005) 14(11):1443-14447.
   PubMed Web of Science ®Google Scholar
• BAUER EA, VALLE JK: Colchicine-induced modulation of collagenase in human skin fibroblast-cultures. J. Invest. Dermatol. (1982) 79:398-403.
   PubMed Web of Science ®Google Scholar
• HERBERT CM, LINDBERG KA, JAYASON MI, BAILEY AJ: Biosynthesis and maturation of skin collagen in scleroderma and effect of D-penicillamine. Lancet (1974) 1:187-192.
   PubMed Web of Science ®Google Scholar
• KING TE Jr: Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Respir. Crit. Care Med. (2005) 172:268-279.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (RAPA. rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biol. Chem. (1998) 31:335-340.
   PubMed Web of Science ®Google Scholar
• SIMLER NR, HOWELL DCJ, MARSHALL RP et al.: The rapamycin analogue SDZ RAD attenuated bleomycin-induced pulmonary fibrosis in rats. Eur. Respir. J. (2002) 19:1124-1127.
   PubMed Web of Science ®Google Scholar
• MURPHY KM, OUYANG W, FARRAR JD et al.: Signaling and transcription in T helper development. Annu. Rev. Immunol. (2000) 18:451-494.
   PubMed Web of Science ®Google Scholar
• WYNN TA: Fibrotic disease and the T(H)1/T(H2 paradigm. Nat. Rev. Immunol. (2004) 4(8):583-594.
   PubMed Web of Science ®Google Scholar
• ZIESCHE R, HOFBAUER E, WITTMANN K, PETKOV V, BLOCK LH: A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. (1999) 341(17):1264-1269.
   PubMed Web of Science ®Google Scholar
• OKADA T, SUGIE I, AISAKA K: Effects of γ-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res. (1993) 12:87-91.
   PubMedGoogle Scholar
• BAJWA EK, AYAS NT, SCHULZER M, MAK E, RYU JH, MALHOTRA A: Interferon γ-1b therapy in idiopathic pulmonary fibrosis: a meta analysis. Chest (2005) 128:203-206.
   PubMed Web of Science ®Google Scholar
• RAGHU G, BROWN KK, BRADFORD WZ et al.: A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. (2004) 350(2):125-133.
   PubMed Web of Science ®Google Scholar
• DU BOIS RM: Interferon γ-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. (1999) 341:1302-1304.
   PubMed Web of Science ®Google Scholar
• HONORE I, NUNES H, GROUSSARD O et al.: Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2003) 167(7):953-957.
   PubMed Web of Science ®Google Scholar
• CHEN ES, GREENLEE BM, WILLS-KARP M, MOLLER DR: Attenuation of lung inflammation and fibrosis in interferon-γ-deficient mice after intratracheal bleomycin. Am. J. Respir. Cell Mol. Biol. (2001) 24(5):545-555.
   PubMed Web of Science ®Google Scholar
• WANG BZ, ZHENG T, ZHU Z et al.: Interferon γ induction of pulmonary emphysema in adult murine lung. J. Exp. Med. (2000) 192(11):1587-1599.
   PubMed Web of Science ®Google Scholar
• BOUROS D, ANTNIOU KM, TZOUVELEKIS A, SIAFAKAS NM: Interferon γ-1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Biol. Ther. (2006) 6(10):1051-1060.
   PubMed Web of Science ®Google Scholar
• PACANOWSKI MA, AMSDN GW: Interferon γ-1b in the treatment of idiopathic pulmonary fibrosis. Ann. Pharmacother. (2005) 39:1678-1686.
   PubMed Web of Science ®Google Scholar
• PIGUET PF: Is “tumor necrosis factor” the major effector of pulmonary fibrosis? Eur. Cytokine Netw. (1990) 1(4):257-258.
   PubMedGoogle Scholar
• LUNDBLAD LK, THOMPSON-FIGUEROA J, LECLAIR T et al.: TNF-α over-expression in lung disease: a single cause behind a complex phenotype. Am. J. Respir. Crit. Care Med. (2005) 171:1363-1370.
   PubMed Web of Science ®Google Scholar
• ZHANG K, GHARAEE-KERMANI M, MCGARRY B REMICK D, PHAN SH: TNF-α mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J. Immunol. (1997) 158:954-959.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, COLLART MA, GRAU GE, KAPANCI Y, VASSALLI P: TNF/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. (1989) 170(3):655-663.
   PubMed Web of Science ®Google Scholar
• ZHAG Y, LEE TC, GUILLEMIN B, YU MC, ROM WN: Enhanced IL-1β and TNF-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis after asbestos exposure. J. Immunol. (1993) 150:4188-4196.
   PubMed Web of Science ®Google Scholar
• PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. (1994) 7(3):515-518.
   PubMed Web of Science ®Google Scholar
• ORTIZ LA, LASKY J, LUNGARELLA G et al.: Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am. J. Respir. Cell Mol. Biol. (1999) 20(4):825-833.
   PubMed Web of Science ®Google Scholar
• LIU JY, BRASS DM, HOYLE GW, BRODY AR: TNF-α receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am. J. Pathol. (1998) 153(6):1839-1847.
   PubMed Web of Science ®Google Scholar
• FUJITA M, SHANNON JM, MORIKAWA O, GAULDIE J, HARA N, MASON RJ: Overexpression of TNF-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β. Am. J. Respir. Cell Mol. Biol. (2003) 29(6):669-676.
   PubMed Web of Science ®Google Scholar
• LIU JY, BRODY AR: Increased TGF-β1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-α receptor knockout mice. J. Environ. Pathol. Toxicol. Oncol. (2001) 20:97-108.
   PubMedGoogle Scholar
• FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. (2001) 19:163-196.
   PubMed Web of Science ®Google Scholar
• NIDEN A, KOSS M, BOYLEN CT, WILCOX A: An open label pilot study to determine the potential efficacy of TNFR: Fc (Enbrel, Etanercept) in the treatment of usual interstitial pneumonitis. Am. J. Respir. Crit. Care Med. (2002) 165(8):A728 (Abstract).
   Google Scholar
• GIRI SN: Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu. Rev. phamacol. Toxicol. (2003) 43:73-95.
   PubMed Web of Science ®Google Scholar
• TZORTZAKI EG, ANTONIOU KM, AERVOU MI et al.: Effects of antifibrotic agents on TGF-β1, CTGF and IFN-γ expression in patients with idiopathic pulmonary fibrosis. Respir. Med. (2007) 101(8):1821-1829.
   PubMed Web of Science ®Google Scholar
• DUNCAN MR, FRAZIER KS, ABRAMSON S et al.: Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: down-regulation by cAMP. FASEB J. (1999) 13(13):1774-1786.
   PubMed Web of Science ®Google Scholar
• LASKY JA, ORTIZ LA, TONTHAT B et al.: Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. (1998) 275(2 Part 1):L365-L371.
   PubMed Web of Science ®Google Scholar
• PAN LH, YAMAUCHI K, UZUKI M et al.: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. (2001) 17(6):1220-1227.
   PubMed Web of Science ®Google Scholar
• KHALIL N, GREENBER AH: The role of TGF-β in pulmonary fibrosis. In: Clinical Aplications of TGF-β (Volume 157). Bock GR, Marsh J (Eds), Ciba Foundation Symposium, John Willy & Sons, New York, USA (1991):194-211.
   Google Scholar
• THANNICKAL VJ, LEE DY, WHITE ES et al.: Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. (2003) 278(14):12384-12389.
   PubMed Web of Science ®Google Scholar
• SIME PJ, XING Z, GRAHAM FL et al.: Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. (1997) 100(4):768-776.
   PubMed Web of Science ®Google Scholar
• TOMASEK JJ, GABBIANI G, HINZ B, CHAPONNER C, BROWN RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. (2002) 3(5):349-363.
   PubMed Web of Science ®Google Scholar
• ZHANG HY, PHAN SH: Inhibition of myofibroblast apoptosis by transforming growth factor β(1). Am. J. Respir. Cell Mol. Biol. (1999) 21(6):658-665.
   PubMed Web of Science ®Google Scholar
• HOROWITZ JC, LEE DY, WAGHRAY M et al.: Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. (2004) 279(2):1359-1367.
   PubMed Web of Science ®Google Scholar
• ROY SG, NOZAKI Y, PHAN SH: Regulation of α-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int. J. Biochem. Cell Biol. (2001) 33:723-734.
   PubMed Web of Science ®Google Scholar
• HAGIMOTO N, KUWANO K, INOSHIMA I et al.: TGF-β1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. Immunol. (2002) 168(12):6470-6478.
   PubMed Web of Science ®Google Scholar
• WILLIS BC, LIEBLER JM, LUBY-PHELPS K et al.: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-{β}1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. (2005) 166(5):1321-1332.
   PubMed Web of Science ®Google Scholar
• JAIN R, SHAUL PW, BOROK Z, WILLIS BC: Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGFβ1. Am. J. Respir. Cell Mol. Biol. (2007) 37:38-47.
   PubMed Web of Science ®Google Scholar
• SELMAN M, RUIZ V, CABRERA S et al.: TIMPs-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. Am. J. Physiol. (2000) 279:L562-L574.
   PubMed Web of Science ®Google Scholar
• KUNUGI S, FUKUDA Y, ISHIZAKI M, YAMANAKA N: Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab. Invest. (2001) 81:1309-1318.
   PubMed Web of Science ®Google Scholar
• MCGUIRE JK, LI Q, PARKS WC: Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. (2003) 162:1831-1843.
   PubMed Web of Science ®Google Scholar
• CUTRONEO KR, WHITE SL, PHAN SH, EHRLICH PH: Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. J. Cell. Physiol. (2007) 211:585-589.
   PubMed Web of Science ®Google Scholar
• BORDER WA, NOBLE NA: Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. (1994) 331(19):1286-1292.
   PubMed Web of Science ®Google Scholar
• BROEKELMANN TJ, LIMPER AH, COLBY TV, MCDONALD JA: Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA (1991) 88(15):6642-6646.
   PubMed Web of Science ®Google Scholar
• KHALIL N, O'CONNOR RN, UNRUH HW et al.: Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. (1991) 5(2):155-162.
   PubMed Web of Science ®Google Scholar
• ZHANG K, REKHTER MD, GORDON D, PHAN SH: Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. Pathol. (1994) 145(1):114-125.
   PubMed Web of Science ®Google Scholar
• GURUJEYALAKSHMI G, HOLLINGER MA, GIRI SN: Regulation of transforming growth factor-β1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis. Am. J. Respir. Cell Mol. Biol. (1998) 18:334-342.
   PubMed Web of Science ®Google Scholar
• LETTERIO JJ, ROBERTS AB: Transforming growth factor-β1-deficient mice: identification of isomer-specific activities in vivo. J. Leuk. Biol. (1996) 59:769-774.
   PubMed Web of Science ®Google Scholar
• YANG YA, DUKHANINA B, TANG M et al.: Life time exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. (2002) 109:1607-1615.
   PubMed Web of Science ®Google Scholar
• ZHAO J, SHI W, WANG YL et al.: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) 282(3):L585-L593.
   PubMed Web of Science ®Google Scholar
• GIRI SN, HYDE DM, HOLLINGER MA: Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax (1993) 48(10):959-966.
   PubMed Web of Science ®Google Scholar
• WANG Q, WANG Y, HYDE DM et al.: Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax (1999) 54(9):805-812.
   PubMed Web of Science ®Google Scholar
• SHIMIZUKAWA M, EBINA M, NARUMI, KIKUCHI T MUNAKATA H, NUKIWA T: Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 284(3):L526-L532.
   PubMed Web of Science ®Google Scholar
• SIRIWARDENA D, KHAW PT, KING AJ et al.: Human antitransforming growth factor β(2) monoclonal antibody – a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology (2002) 109(3):427-431.
   PubMed Web of Science ®Google Scholar
• ANTONIOU KM, POTAKA A, BOUROS D, SIAFAKAS MN: Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. (2007) 20(5):453-461.
   PubMed Web of Science ®Google Scholar
• DERYNCK R, ZHANG YE: Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature (2003) 425(6958):577-584.
   PubMed Web of Science ®Google Scholar
• HU B, TACK DC, LIU T, WU Z, ULLENBRUCH MR, PHAN SH: Role of Smad3 in the regulation of rat telomerase reverses transcriptase by TGFβ. Oncogene (2006) 25:1030-1041.
   PubMed Web of Science ®Google Scholar
• ZHAO Y, GEVERD DA: Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-β signaling. Biochem. Biophys. Res. Commun. (2002) 294:319-323.
   PubMed Web of Science ®Google Scholar
• HU B, WU Z, PHAN SH: Smad3 mediates transformiong growth factor-β-induced-α-smooth muscle actin expression. Am. J. Respir. Cell Mol. Biol. (2003) 29:397-404.
   PubMed Web of Science ®Google Scholar
• NAKAO A, FUJII M, MATSUMURA R et al.: Transient gene transfer and expression of Smad 7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. (1999) 104:5-11.
   PubMed Web of Science ®Google Scholar
• HUANG M, SHARMA S, ZHU LX et al.: IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J. Clin. Invest. (2002) 109:931-937.
   PubMed Web of Science ®Google Scholar
• SINGH J, LING LE, SAWYER JS, LEE WC, ZHANG F, YINGLING JM: Transforming the TGF-β pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr. Opin. Drug Discov. Dev. (2004) 7(4):437-445.
   PubMed Web of Science ®Google Scholar
• SAWYER JS, BEIGHT DW, BRITT KS et al.: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo [1,2-b] pyrazole inhibitors of the transforming growth factor-β type 1 receptor kinase domain. Bioorg. Med. Chem. Lett. (2004) 14(13):3581-3584.
   PubMed Web of Science ®Google Scholar
• SINGH J, CHUAQUI CE, BORIACK-SJODIN PA et al.: Successful shape-based virtual screening: the discovery of a potent inhibitor of the type 1 TGF-β receptor kinase (TβRI). Bioorg. Med. Chem. Lett. (2003) 13(24):4355-4359.
   PubMed Web of Science ®Google Scholar
• BONNIAUD P, MARGETTS PJ, KOLB M et al.: Progressive transforming growth factor {β}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. (2005) 171(8):889-898.
   PubMed Web of Science ®Google Scholar
• GRYGIELKO ET, MARTIN WM, TWEED CW et al.: Inhibition of gene markers of fibrosis with a novel inhibitor of TGF {β}-type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. (2005) 313(3):943-951.
   PubMed Web of Science ®Google Scholar
• CHAUDHARY NI, ROTH GJ, HILBERG F et al.: Inhibition of PDGF, VEGF and FGF signaling attenuates fibrosis. Eur. Respir. J. (2007) 29(5):976-985.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND AM, ROMARIS M, RASMUSSEN LM et al.: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J. (1994) 302:527-534.
   PubMed Web of Science ®Google Scholar
• KOLB M, MARGETTS PJ, GALT T et al.: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. (2001) 163:770-777.
   PubMed Web of Science ®Google Scholar
• SAVAGE DG, ANTMAN KH: Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med. (2002) 346(9):683-693.
   PubMed Web of Science ®Google Scholar
• DANIELS CE, WILKES MC, EDENS M et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. (2004) 114(9):1308-1316.
   PubMed Web of Science ®Google Scholar
• DISTLER JH, JUNGEL A, HUBER LC et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. (2007) 56(1):9-12.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, OREILLY T, WOOD J: Pharmacology of imatinib (STI571). Eur. J. Cancer (2002) 38(Suppl. 5):S28-S36.
   PubMedGoogle Scholar
• MA CX, HOBDAY TJ, JETT JR: Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin. Proc. (2003) 78(12):1578-1579.
   PubMed Web of Science ®Google Scholar
• ISSHIKI I, YAMAGUCHI K, OKAMOTO S: Interstitial pneumonitis during imatinib therapy. Br. J. Haematol. (2004) 125(4):420.
   PubMedGoogle Scholar
• RAJDA J, PHATAK PD: Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am. J. Hematol. (2005) 79(1):80-81.
   PubMed Web of Science ®Google Scholar
• YAMASAWA H, SUGIYAMA Y, BANDO M, OHNO S: Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration (2006) 528:Doi:10.1159/000091272.
   Google Scholar
• VITTAL R, ZHANG H, HAN MK, MOORE BB, HOROWITZ JC, THANNICKAK VJ: Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment for fibrotic diseases. J. Pharmacol. Exp. Ther. (2007) 321:35-44.
   PubMed Web of Science ®Google Scholar
• PEACOCK AJ, DAWES KE, SHOCK A, GARY AJ, REEVES JT, LAURENT GJ: Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell Mol. Biol. (1992) 7(5):492-499.
   PubMed Web of Science ®Google Scholar
• SHAHAR I, FIREMAN E, TOPILSKY M et al.: Effect of endothelin-1 on α-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int. J. Immunopharmacol. (1999) 21(11):759-775.
   PubMed Web of Science ®Google Scholar
• SHI-WEN X, CHEN Y, DENTON CP et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell (2004) 15(6):2707-2719.
   PubMed Web of Science ®Google Scholar
• XU S, DENTON CP, HOLMES A, DASHWOOD MR, ABRAHAM DJ, BLACK CM: Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. Pharmacol. (1998) 31(Suppl. 1):S360-S363.
   PubMed Web of Science ®Google Scholar
• SHICHIRI M, SEDIVY JM, MARUMO F, HIRATA Y: Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol. Endocrinol. (1998) 12(2):172-180.
   PubMed Web of Science ®Google Scholar
• SHI-WEN X, DENTON CP, DASHWOOD MR et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. (2001) 116(3):417-425.
   PubMed Web of Science ®Google Scholar
• WENDEL M, PETZOLD A, KOSLOWSKI R et al.: Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem. Cell Biol. (2004) 122(5):507-517.
   PubMed Web of Science ®Google Scholar
• PARK SH, SALEH D, GIAID A, MICHEL RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. (1997) 156(2 Part 1):600-608.
   PubMed Web of Science ®Google Scholar
• MUTSAERS SE, MARSHALL RP, GOLDSACK NR, LAURENT GJ, MCANULTY RJ: Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. (1998) 11(2-3):221-225.
   PubMed Web of Science ®Google Scholar
• UGUCCIONI M, PULSATELLI L, GRIGOLO B et al.: Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. (1995) 48(4):330-334.
   PubMed Web of Science ®Google Scholar
• GIAID A, MICHEL RP, STEWART DJ, SHEPPARD M, CORRIN B, HAMID Q: Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet (1993) 341(8860):1550-1554.
   PubMed Web of Science ®Google Scholar
• SALEH D, FURUKAWA K, TSAO MS et al.: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol. (1997) 16(2):187-193.
   PubMed Web of Science ®Google Scholar
• SALANI D, TARABOLETTI G, ROSANO L et al.: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. (2000) 157:1703-1711.
   PubMed Web of Science ®Google Scholar
• FAGAN KA, MCMURTRY IF, RODMAN DM: Role of endothelin-1 in lung disease. Rispir. Res. (2001) 2:90-101.
   PubMed Web of Science ®Google Scholar
• GUNTHER A, ENKE B, MARKART P et al.: safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J. (2007) 29:713-719.
   PubMed Web of Science ®Google Scholar
• CANTIN AM, NORTH SL, FELLS GA, HUBBARD RC, CRYSTAL RG: Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. (1987) 79(6):1665-1673.
   PubMed Web of Science ®Google Scholar
• CANTIN AM, HUBBARD RC, CRYSTAL RG: Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. (1989) 139(2):370-372.
   PubMed Web of Science ®Google Scholar
• BOROK Z, BUHL R, GRIMES GJ et al.: Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet (1991) 338(8761):215-216.
   PubMed Web of Science ®Google Scholar
• MEYER A, BUHL R, MAGNUSSEN H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. (1994) 7(3):431-436.
   PubMed Web of Science ®Google Scholar
• WHITE AC, THANNICKAL VJ, FANBURG BL: Glutathione deficiency in human disease. J. Nutr. Biochem. (1994) 5:218-226.
   Web of Science ®Google Scholar
• RINALDO J, GOLDSTEIN RH, SNIDER GL: Modification of oxygen toxicity after lung injury by bleomycin in hamsters. Am. Rev. Respir. Dis. (1982) 126(6):1030-1033.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA JM, LEVIN JR, HYDE DM, GIRI SN: Repeated exposures to enzyme-generated oxidants cause alveolitis, epithelial hyperplasia, and fibrosis in hamsters. Am. J. Pathol. (1991) 139(6):1485-1499.
   PubMed Web of Science ®Google Scholar
• MANOURY B, NENAN S, LECLERC O et al.: The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir. Res. (2005) 6:11 (Doi:10.1186/1465-9921-6-11).
   PubMed Web of Science ®Google Scholar
• SHAHZEIDI S, SARNSTRAND B, JEFFERY PK, MCANULTY RJ, LAURENT GJ: Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. (1991) 4(7):845-852.
   PubMed Web of Science ®Google Scholar
• CRYSTAL RG: Oxidant and respiratory track epithelial injury pathogenesis and strategies for therapeutic intervention. Am. J. Med. (1991) 91:395-445.
   Google Scholar
• THANNICKAL VJ, FANBURG BL: Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor β1. J. Biol. Chem. (1995) 270(51):30334-30338.
   PubMed Web of Science ®Google Scholar
• THANNICKAL VJ, DAY RM, KLINZ SG, BASTIEN MC, LARIOS JM, FANBURG BL: Ras-dependent and-independent regulation of reactive oxygen species by mitogenic growth factors and TGF-β1. FASEB J. (2000) 14(12):1741-1748.
   PubMed Web of Science ®Google Scholar
• TOMA TP, BHOWMIK A, RAJAKULASINGAM R: Acetylcysteine in pulmonary fibrosis. N. Engl. J. Med. (2005) 354(10):1089-1091.
   Google Scholar
• RAHMAN I, MACNEE W: oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. (2000) 16:534-554.
   PubMed Web of Science ®Google Scholar
• BEHR J, MAIER K, DEGENKOLB B, KROMBACH F, VOGELMEIER C: Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. (1997) 156(6):1897-1901.
   PubMed Web of Science ®Google Scholar
• DEMEDTS M, BEHR J, BUHL R et al.: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. (2005) 353(2):2229-2242.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, PETERS-GOLDEN M, PANETTIERI RA, HENDERSON WR Jr: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. (2003) 111(1 Suppl.):S18-S34; discussion S34-S36.
   PubMedGoogle Scholar
• SHIM YM, ZHU Z, ZHENG T et al.: Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. J. Immunol. (2006) 177(3):1918-1924.
   PubMed Web of Science ®Google Scholar
• WILBORN J, BAILIE M, COFFEY M, BURDICK M, STRIETER R, PERERS-GOLDEN M: Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. (1996) 97(8):1827-1836.
   PubMed Web of Science ®Google Scholar
• BOROK Z, GILLISSEN A, BUHL R et al.: Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am. Rev. Respir. Dis. (1991) 144(5):1080-1084.
   PubMed Web of Science ®Google Scholar
• WILBORN J, CROFFORD LJ, BURDICK MD, KUNKEL SL, STRIETER RM, PERERS-GOLDEN M: Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J. Clin. Invest. (1995) 95(4):1861-1868.
   PubMed Web of Science ®Google Scholar
• LAMA V, MOORE BB, CHRISTENSEN P, TOEWS GB, PETERS-GOLDEN M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am. J. Respir. Cell Mol. Biol. (2002) 27(6):752-758.
   PubMed Web of Science ®Google Scholar
• KOHYAMA T, ERTL RF, VALENTI V et al.: Prostaglandin E(2) inhibits fibroblast chemotaxis. Am. J. Physiol. Lung. Cell Mol. Physiol. (2001) 281(5):L1257-L1263.
   PubMed Web of Science ®Google Scholar
• MIO T, LIU XD, ADACHI Y et al.: Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am. J. Physiol. (1998) 274(1 Part 1):L119-L126.
   PubMed Web of Science ®Google Scholar
• KOLODSICK JE, PETERS-GOLDEN M, LARIOS J, TOEWS GB, THANNICKAL VJ, MOORE BB: Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. (2003) 29(5):537-544.
   PubMed Web of Science ®Google Scholar
• THOMAS EP, PETERS-GOLDEN M, WHITE ES: PGE2 inhibition of TGF-β1-induced myofibroblast differention is smad-independent but involves cell shape and adhesion-dependent signaling. Am. J. Physiol. Lung Cell Mol. Physiol. (2007) (Article in Press). Doi:1152/ajplung.00489.2006.
   Google Scholar
• PETERS-GOLDEN M, BAILIE M, MARSHALL T et al.: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. (2002) 165(2):229-235.
   PubMed Web of Science ®Google Scholar
• FAILLA M, GENOVSE T, MAZZON E et al.: Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir. Res. (2006) 7:137.
   PubMed Web of Science ®Google Scholar
• ROBIN P, MOLLISON KW: Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostagland. Lipid Mediat. (2007) 83:188-197.
   PubMed Web of Science ®Google Scholar
• KEANE MP: Angiogenesis and pulmonary fibrosis. Feast or famine? Editorial. Am. J. Respir. Crit. Care Med. (2004) 170:207.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp. Biol. Med. (Maywood) (2001) 226(7):665-673.
   PubMed Web of Science ®Google Scholar
• MAMOU F, MAY KS, SCHIPPER MJ et al.: Tetrathiomolybdate blocks bFGF-but not VEGF-induced incipient angiogenesis in vitro. Anticancer Res. (2006) 26(3A):1753-1758.
   PubMed Web of Science ®Google Scholar
• BREWER GJ, ULLENBRUCH MR, DICK, OLIVAREZ L, PHAN SH: Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J. Lab. Clin. Med. (2003) 141(3):210-216.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J. Cell Mol. Med. (2003) 7(1):11-20.
   PubMed Web of Science ®Google Scholar
• BREWER GJ, DICK R, ULLENBRUCH MR et al.: Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J. Inorg. Biochem. (2004) 98(12):2160-2167.
   PubMed Web of Science ®Google Scholar
• MARTIN EZ FJ: Idiopathic interstitial pneumonias: usual interstitial pneumonia versus non specific interstitial pneumonia. Proc. Am. Throac. Soc. (2006) 3:81-95.
   PubMedGoogle Scholar